The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Subscribe To Our Newsletter & Stay Updated
